A partner walks into the room and says they want out. From inside the practice, this looks like an equity event with three exits: sell to private equity, bring in an outside investor, or write a personal check. There is a fourth. The practice entity can borrow to fund the buyout — and lenders actively write this transaction.
Key Takeaways:
- A physician practice partner buyout does not require selling to PE. The practice entity can borrow to fund the departing partner’s exit.
- Remaining physicians retain 100% equity post-close. Debt service comes from the practice’s existing cash flows.
- The key underwriting variable is physician revenue concentration. High concentration has produced real lender losses; this is scrutinized carefully.
What is a physician practice partner buyout, and who finances it?
A partner buyout is the purchase of a departing physician’s equity stake by the practice itself. The departing partner is retiring, relocating, or ready to move on. Their ownership interest has to be priced and paid for.
The American College of Physicians addresses partner buy-ins and buyouts in its practice management guidance, noting installment payments from practice cash flow as a common mechanism groups use. At platform scale, those cash flows can support a dedicated financing rather than a slow drip from operating accounts.
This is practice partner buyout financing as a distinct product: a cash-flow loan sized off EBITDA, not an asset-based facility sized off receivables.
How does the financing structure work?
Most multi-partner practices at this scale operate under a split-entity model. A professional corporation or PLLC holds the clinical license and employs the physicians. A management services organization (the MSO) owns the administrative infrastructure — billing, credentialing, IT, payor contracting, and physical assets — tied together by a management services agreement (MSA).
The MSO is typically the borrowing entity. In states with Corporate Practice of Medicine (CPOM) restrictions, which prohibit non-physician entities from directly employing physicians or owning clinical operations, the physician practice cannot grant a direct lien to a third-party lender. The MSO, holding non-clinical assets, can. In practice this creates a “back-to-back” lien structure: the lender takes a security interest in the MSA itself via collateral assignment, plus UCC filings and deposit account control agreements against the physician PC (DLA Piper, “Healthcare Lending Transactions: Key Considerations,” September 2023). CPOM enforcement varies materially by jurisdiction — some states apply it strictly, others are more permissive — so the structure is tailored to the applicable state rules.
Three clean structures emerge in practice:
| Structure | How it works | When it fits |
|---|---|---|
| Debt to the entity | The MSO or holdco borrows, buys out the departing partner’s equity stake, repays from operating cash flows | Platforms with sufficient EBITDA; cleanest path |
| Seller financing | The departing partner takes part of the price in installments over 3–7 years | Complement to senior debt; smaller tranche, tax-efficient for seller |
| Hybrid | Third-party debt for the majority of the price, seller carry for a portion (often 10–25%) | When the full price would push leverage beyond a single tranche |
In the entity-debt path, the remaining physicians retain 100% of the equity. The departing partner’s stake is valued at a multiple of normalized earnings — almost always lower than what a PE buyer would pay at a full platform exit. That discount is what makes the debt-financed path economically viable for the remaining partners.
How do lenders evaluate these deals?
The underwriting variable that receives the most scrutiny is physician concentration risk. Healthcare lending has accumulated enough history to make concentration a hard underwriting focus: practices with materially lower concentration in their top-producing physician can command meaningfully higher valuations, all else equal. Lenders typically underwrite to a haircut on physician revenue projections to model a departure scenario, and physician turnover appears explicitly as an event of default trigger in most healthcare lending agreements.
Payor mix is the second major variable. Commercial-heavy revenue is strongly preferred. A 12-physician MSO where the departing partner generates 8% of revenue is a different credit from a two-partner practice where one generates half.
On leverage, the financing route matters. Bank-financed smaller partner buyouts may see EBITDA leverage in the 2.5x–3.5x range. For mid-market platforms financed by direct lenders or private credit — where most physician practice transactions above the community level are executed — leverage runs 3.5x–5.5x, with diversified payor mix and seasoned management accessing the upper end. Private credit has expanded materially into healthcare practice buyouts, with deal flow concentrated in physician practices, dental, and behavioral health — a pattern tracked across White & Case’s Debt Explorer and corroborated by deal volume data from multiple advisory sources.
What are the alternatives when a partner wants out?
| Path | Control after | The tradeoff |
|---|---|---|
| Debt-financed buyout | Remaining physicians own 100% | Adds leverage for a contained purpose; keeps the upside |
| PE recap | New PE-backed entity holds majority; physicians roll a minority | Exit timeline and governance shift to the PE firm’s fund lifecycle |
| Full sale | Nobody continues | The practice as an independent enterprise ends |
A PE recap is not a partner buyout. It is a recapitalization with a new majority owner operating on a fund lifecycle — typically five to seven years to an eventual exit. Research published through NIH’s PMC notes PE buyouts commonly finance 70–80% of the purchase price with debt carried by the practice. Either way, the practice’s revenues service the debt. The question is who owns the practice while they do. A debt-financed buyout keeps that ownership with the remaining physicians. We have written about this tradeoff in the context of healthcare services platforms generally (how the debt-versus-PE decision plays out).
What to plan for
Two considerations belong in any financing conversation. First, covenant structure should account for reimbursement variability — a well-built package leaves cushion above closing leverage to absorb a moderate disruption without triggering a technical default. Second, a partner buyout is a continuity event, not a growth event. Confirm the structure preserves room to grow: a revolver alongside the term loan, or a delayed-draw term loan if acquisition-led growth is on the horizon, keeps the practice from returning for a waiver the moment it wants to expand.
When a partner says they want out, the remaining physicians now have what they need to respond on their own terms. They know the physician practice partner buyout exists as a financeable path, and they know the questions to bring to a lender. The fourth option was there all along.
